Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis | MicrobiomeTrials← Back to trialsNCT05184088
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2023-01-13Est. Completion: 2026-04-21
Enrollment target: 244 participants Locations- St Luke's Hospital, Kansas City, Kansas, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Augsburg, Augsburg, Germany
- Charite Berlin, Berlin, Germany
- University of Essen, Essen, Germany
- HOPA Hamburg, Hamburg, Germany
- University of Heidelberg, Heidelberg, Germany
- University of Würzburg, Würzburg, Germany
- Hospital University Bellvitge, Barcelona, Spain
- Hospital University Puerta de Hierro, Madrid, Spain
- Clínica Universidad de Navarra, Pamplona, Spain
- University of Salamanca, Salamanca, Spain
- Royal Free Hospital, London, United Kingdom
Other microbiome trials you might be interested in
Heart Failure
The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.
Mesa, United StatesEst. completion Aug 15, 2035
Mild Cognitive Impairment (MCI)
Because of the lengthening of life expectancy, more and more people are concerned with the effects of aging on their men…
Marseille, FranceCompleted Aug 11, 2023